Characterization of B cells in muscle-specific kinase antibody myasthenia gravis.

dc.contributor.author

Guptill, Jeffrey T

dc.contributor.author

Yi, John S

dc.contributor.author

Sanders, Donald B

dc.contributor.author

Guidon, Amanda C

dc.contributor.author

Juel, Vern C

dc.contributor.author

Massey, Janice M

dc.contributor.author

Howard, James F

dc.contributor.author

Scuderi, Flavia

dc.contributor.author

Bartoccioni, Emanuela

dc.contributor.author

Evoli, Amelia

dc.contributor.author

Weinhold, Kent J

dc.coverage.spatial

United States

dc.date.accessioned

2015-06-06T19:17:55Z

dc.date.issued

2015-04

dc.description.abstract

OBJECTIVE: To characterize B-cell subsets in patients with muscle-specific tyrosine kinase (MuSK) myasthenia gravis (MG). METHODS: In accordance with Human Immunology Project Consortium guidelines, we performed polychromatic flow cytometry and ELISA assays in peripheral blood samples from 18 patients with MuSK MG and 9 healthy controls. To complement a B-cell phenotype assay that evaluated maturational subsets, we measured B10 cell percentages, plasma B cell-activating factor (BAFF) levels, and MuSK antibody titers. Immunologic variables were compared with healthy controls and clinical outcome measures. RESULTS: As expected, patients treated with rituximab had high percentages of transitional B cells and plasmablasts and thus were excluded from subsequent analysis. The remaining patients with MuSK MG and controls had similar percentages of total B cells and naïve, memory, isotype-switched, plasmablast, and transitional B-cell subsets. However, patients with MuSK MG had higher BAFF levels and lower percentages of B10 cells. In addition, we observed an increase in MuSK antibody levels with more severe disease. CONCLUSIONS: We found prominent B-cell pathology in the distinct form of MG with MuSK autoantibodies. Increased BAFF levels have been described in other autoimmune diseases, including acetylcholine receptor antibody-positive MG. This finding suggests a role for BAFF in the survival of B cells in MuSK MG, which has important therapeutic implications. B10 cells, a recently described rare regulatory B-cell subset that potently blocks Th1 and Th17 responses, were reduced, which suggests a potential mechanism for the breakdown in immune tolerance in patients with MuSK MG.

dc.identifier

http://www.ncbi.nlm.nih.gov/pubmed/25745635

dc.identifier

NEURIMMINFL2014002246

dc.identifier.uri

https://hdl.handle.net/10161/10206

dc.language

eng

dc.publisher

Ovid Technologies (Wolters Kluwer Health)

dc.relation.ispartof

Neurol Neuroimmunol Neuroinflamm

dc.relation.isversionof

10.1212/NXI.0000000000000077

dc.title

Characterization of B cells in muscle-specific kinase antibody myasthenia gravis.

dc.type

Journal article

duke.contributor.orcid

Yi, John S|0000-0001-7777-2437

duke.contributor.orcid

Sanders, Donald B|0000-0003-2320-4965

duke.contributor.orcid

Juel, Vern C|0000-0002-2917-2995

pubs.author-url

http://www.ncbi.nlm.nih.gov/pubmed/25745635

pubs.begin-page

e77

pubs.issue

2

pubs.organisational-group

Basic Science Departments

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Duke

pubs.organisational-group

Duke Cancer Institute

pubs.organisational-group

Duke Clinical Research Institute

pubs.organisational-group

Duke Human Vaccine Institute

pubs.organisational-group

Immunology

pubs.organisational-group

Institutes and Centers

pubs.organisational-group

Neurology

pubs.organisational-group

Neurology, Neuromuscular Disease

pubs.organisational-group

Pathology

pubs.organisational-group

School of Medicine

pubs.organisational-group

Surgery

pubs.organisational-group

Surgery, Surgical Sciences

pubs.publication-status

Published online

pubs.volume

2

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Characterization of B cells in muscle-specific kinase antibody myasthenia gravis..pdf
Size:
402.92 KB
Format:
Adobe Portable Document Format
Description:
Published version